B-intervention	0	9	Cisplatin
I-intervention	10	14	plus
I-intervention	15	19	oral
I-intervention	20	29	etoposide
O	30	31	(
O	31	34	EoP
O	34	35	)
O	36	47	combination
O	48	50	is
O	51	55	more
O	56	65	effective
O	66	70	than
B-control	71	81	paclitaxel
O	82	84	in
B-eligibility	85	93	patients
I-eligibility	94	98	with
I-eligibility	99	107	advanced
I-eligibility	108	114	breast
I-eligibility	115	121	cancer
I-eligibility	122	132	pretreated
I-eligibility	133	137	with
I-eligibility	138	152	anthracyclines
O	152	153	:
O	154	155	a
O	156	166	randomised
O	167	172	phase
O	173	176	III
O	177	182	trial
O	183	185	of
B-ethinicity	186	193	Turkish
O	194	202	Oncology
O	203	208	Group
O	208	209	.

O	210	213	Our
O	214	223	objective
O	224	227	was
O	228	230	to
O	231	240	determine
O	241	248	whether
O	249	253	oral
O	254	263	etoposide
O	264	267	and
O	268	277	cisplatin
O	278	289	combination
O	290	291	(
O	291	294	EoP
O	294	295	)
O	296	298	is
O	299	307	superior
O	308	310	to
O	311	321	paclitaxel
O	322	324	in
O	325	328	the
O	329	338	treatment
O	339	341	of
O	342	350	advanced
O	351	357	breast
O	358	364	cancer
O	365	366	(
O	366	369	ABC
O	369	370	)
O	371	379	patients
O	380	390	pretreated
O	391	395	with
O	396	410	anthracyclines
O	410	411	.

O	412	416	From
O	417	425	December
O	426	430	1997
O	431	433	to
O	434	440	August
O	441	445	2003
O	445	446	,
B-total-participants	447	450	201
O	451	459	patients
O	460	464	were
O	465	475	randomised
O	475	476	,
B-intervention-participants	477	480	100
O	481	483	to
O	484	487	EoP
O	488	491	and
B-control-participants	492	495	101
O	496	498	to
O	499	509	paclitaxel
O	510	514	arms
O	514	515	.

O	516	520	Four
O	521	529	patients
O	530	532	in
O	533	537	each
O	538	541	arm
O	542	546	were
O	547	557	ineligible
O	557	558	.

O	559	562	The
O	563	568	doses
O	569	571	of
O	572	581	etoposide
O	582	585	and
O	586	595	cisplatin
O	596	600	were
O	601	603	50
O	604	606	mg
O	607	608	p
O	608	609	.
O	609	610	o
O	610	611	.
O	612	617	twice
O	618	619	a
O	620	623	day
O	624	627	for
O	628	629	7
O	630	634	days
O	635	638	and
O	639	641	70
O	642	644	mg
O	645	646	m
O	646	647	(
O	647	648	-
O	648	649	2
O	649	650	)
O	651	664	intravenously
O	665	666	(
O	666	667	i
O	667	668	.
O	669	670	v
O	670	671	.
O	671	672	)
O	673	675	on
O	676	679	day
O	680	681	1
O	681	682	,
O	683	695	respectively
O	695	696	,
O	697	700	and
O	701	703	it
O	704	707	was
O	708	711	175
O	712	714	mg
O	715	716	m
O	716	717	(
O	717	718	-
O	718	719	2
O	719	720	)
O	721	723	on
O	724	727	day
O	728	729	1
O	730	733	for
O	734	744	paclitaxel
O	744	745	.

O	746	750	Both
O	751	761	treatments
O	762	766	were
O	767	775	repeated
O	776	781	every
O	782	783	3
O	784	789	weeks
O	789	790	.

O	791	792	A
O	793	799	median
O	800	802	of
O	803	807	four
O	808	814	cycles
O	815	817	of
O	818	823	study
O	824	833	treatment
O	834	837	was
O	838	843	given
O	844	846	in
O	847	851	both
O	852	856	arms
O	856	857	.

O	858	861	The
B-outcome	862	870	response
I-outcome	871	875	rate
O	876	884	obtained
O	885	887	in
O	888	891	the
O	892	895	EoP
O	896	899	arm
O	900	903	was
O	904	917	significantly
O	918	924	higher
O	925	926	(
B-iv-bin-percent	926	928	36
I-iv-bin-percent	928	929	.
I-iv-bin-percent	929	930	3
O	931	933	vs
B-cv-bin-percent	934	936	22
I-cv-bin-percent	936	937	.
I-cv-bin-percent	937	938	2
I-cv-bin-percent	938	939	%
O	939	940	;
O	941	942	P
O	942	943	=
O	943	944	0
O	944	945	.
O	945	948	038
O	948	949	)
O	949	950	.

B-outcome	951	957	Median
I-outcome	958	966	response
I-outcome	967	975	duration
O	976	979	was
O	980	986	longer
O	987	990	for
O	991	994	the
O	995	998	EoP
O	999	1002	arm
O	1003	1004	(
B-iv-cont-median	1004	1005	7
O	1006	1008	vs
B-cv-cont-median	1009	1010	4
I-cv-cont-median	1011	1017	months
O	1017	1018	)
O	1019	1020	(
O	1020	1021	P
O	1021	1022	=
O	1022	1023	0
O	1023	1024	.
O	1024	1027	132
O	1027	1028	)
O	1028	1029	.

O	1030	1034	Also
O	1034	1035	,
B-outcome	1036	1040	time
I-outcome	1041	1043	to
I-outcome	1044	1055	progression
O	1056	1059	was
O	1060	1073	significantly
O	1074	1076	in
O	1077	1083	favour
O	1084	1086	of
O	1087	1090	the
O	1091	1094	EoP
O	1095	1098	arm
O	1099	1100	(
B-iv-cont-median	1100	1101	5
I-iv-cont-median	1101	1102	.
I-iv-cont-median	1102	1103	5
O	1104	1106	vs
B-cv-cont-median	1107	1108	3
I-cv-cont-median	1108	1109	.
I-cv-cont-median	1109	1110	9
I-cv-cont-median	1111	1117	months
O	1117	1118	;
O	1119	1120	P
O	1120	1121	=
O	1121	1122	0
O	1122	1123	.
O	1123	1126	003
O	1126	1127	)
O	1127	1128	.

B-outcome	1129	1135	Median
I-outcome	1136	1143	overall
I-outcome	1144	1152	survival
O	1153	1156	was
O	1157	1162	again
O	1163	1176	significantly
O	1177	1183	longer
O	1184	1186	in
O	1187	1190	the
O	1191	1194	EoP
O	1195	1198	arm
O	1199	1200	(
B-iv-cont-median	1200	1202	14
O	1203	1205	vs
B-cv-cont-median	1206	1207	9
I-cv-cont-median	1207	1208	.
I-cv-cont-median	1208	1209	5
I-cv-cont-median	1210	1216	months
O	1216	1217	;
O	1218	1219	P
O	1219	1220	=
O	1220	1221	0
O	1221	1222	.
O	1222	1225	039
O	1225	1226	)
O	1226	1227	.

B-outcome	1228	1236	Toxicity
I-outcome	1237	1244	profile
O	1245	1247	of
O	1248	1252	both
O	1253	1259	groups
O	1260	1263	was
O	1264	1271	similar
O	1271	1272	.

B-iv-bin-abs	1273	1276	Two
O	1277	1285	patients
O	1286	1288	in
O	1289	1293	each
O	1294	1297	arm
O	1298	1302	were
B-outcome	1303	1307	lost
I-outcome	1308	1311	due
I-outcome	1312	1314	to
I-outcome	1315	1322	febrile
I-outcome	1323	1334	neutropenia
O	1334	1335	.

O	1336	1339	The
O	1340	1348	observed
O	1349	1357	activity
O	1358	1361	and
O	1362	1372	acceptable
O	1373	1381	toxicity
O	1382	1384	of
O	1385	1388	EoP
O	1389	1397	endorses
O	1398	1401	the
O	1402	1412	employment
O	1413	1415	of
O	1416	1420	this
O	1421	1432	combination
O	1433	1435	in
O	1436	1439	the
O	1440	1449	treatment
O	1450	1452	of
O	1453	1456	ABC
O	1457	1466	following
O	1467	1481	anthracyclines
O	1481	1482	.
